Biopharma firm Impact Therapeutics completes Series D1 financing
Category: #health  By Pankaj Singh  Date: 2022-03-14
 | 
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Biopharma firm Impact Therapeutics completes Series D1 financing

Impact Therapeutics, a biopharmaceutical company, has reportedly announced the completion of its Series D1 financing.

Dingxin Capital, C&D EMERGING CAPITAL, CCBT, Sam Isaly-led Exome Asset Management are some of the new investors that took part in this round along with current shareholders China Summit, LAV (Lilly Asia Ventures), and Yuexiu.

The funds will be utilized to expedite the development of its synthetic lethality programs, several of which are showcasing top potential.

Last year, Impact Therapeutics attained milestones across several targets including Wee1, PARP, and ATR, becoming one of the biotech firms with the world’s broadest DDR (DNA damage response) pipelines and is broadening to other advanced synthetic lethality targets to widen its pipelines. The company already has three synthetic lethality compounds currently in the clinical stage.

According to the Chief Executive Officer and President of Impact Therapeutics Dr. Jun Bao, the successful closure of this transaction gave the company more confidence to execute its strategy of global development and rapidly advance different clinical trials.

For the record, Impact Therapeutics is committed to discovering and developing synthetic lethality-based targeted anti-cancer therapeutics. The company has mustered one of the most complete DDR global pipelines of advanced drug candidates produced by in-house discovery efforts and is broadening to other advanced synthetic lethality targets to expand its pipeline.

Some of the products of the Impact pipeline include Wee1 inhibitor (IMP7068), ATR inhibitor (IMP9064), PARP inhibitor (Senaparib/ IMP4297), and other advanced DDR pathway inhibitors. PARP inhibitor (Senaparib/ IMP4297), the lead clinical program, is currently in Phase II/III studies for small cell lung cancer, prostate cancer, ovarian cancer, and other indications globally including China.

The preliminary clinical data of Senaparib exhibited superior tolerability and broader therapeutic windows in comparison to other PARPi. Wee1 inhibitor (IMP7068)’s Phase I study is performed worldwide. FDA has provided IND Clearance to ATR Inhibitor IMP9064 to initiate clinical studies in the United States and provided clinical application in China.

Source credit:

https://www.prnewswire.com/news-releases/impact-therapeutics-announces-completion-of-series-d1-financing-301501583.html



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

Rona Therapeutics obtains global rights to Sanofi's siRNA platform

Rona Therapeutics obtains global rights to Sanofi's siRNA platform

By Pankaj Singh

Rona Therapeutics Inc has reportedly acquired the global exclusive rights to the siRNA platform of delivery moiety and chemical modification from Sanofi S.A., in addition to four pre-clinical contenders for unrevealed ...

Toy maker Mattel inks multi-year agreement with Elon Musk’s SpaceX

Toy maker Mattel inks multi-year agreement with Elon Musk’s SpaceX

By Pankaj Singh

California-based toy manufacturing and entertainment company, Mattel, has recently signed a multi-year agreement with Elon Musk’s private spaceflight company, SpaceX.

T...

USHV partners with Willowbrook to provide quality cardiovascular care

USHV partners with Willowbrook to provide quality cardiovascular care

By Pankaj Singh

US Heart & Vascular (USHV) is reportedly partnering with Willowbrook Cardiovascular Associates to offer quality cardiovascular care in the Houston market.

USHV has a strong ma...